Mitapivat

Mitapivat, sold under the brand name Pyrukynd, is a medication used to treat hemolytic anemia.[1] It is taken as the sulfate hydrate salt by mouth.[1]

Mitapivat
Clinical data
Trade namesPyrukynd
Other namesAG-348, Mitapivat sulfate (USAN US)
License data
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC24H26N4O3S
Molar mass450.56 g·mol−1
3D model (JSmol)
  • O=C(N1CCN(CC2CC2)CC1)C1=CC=C(NS(=O)(=O)C2=CC=CC3=C2N=CC=C3)C=C1
  • InChI=1S/C24H26N4O3S/c29-24(28-15-13-27(14-16-28)17-18-6-7-18)20-8-10-21(11-9-20)26-32(30,31)22-5-1-3-19-4-2-12-25-23(19)22/h1-5,8-12,18,26H,6-7,13-17H2
  • Key:XAYGBKHKBBXDAK-UHFFFAOYSA-N

Mitapivat is a pyruvate kinase activator.[1]

Mitapivat was approved for medical use in the United States in February 2022.[1][2][3]

Medical uses

Mitapivat is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.[1][3]

Pharmacology

Mechanism of action

Mitapivat binds to and activates pyruvate kinase, thereby enhancing glycolytic pathway activity, improving adenosine triphosphate (ATP) levels and reducing 2,3-diphosphoglycerate (2,3-DPG) levels.[4] Mutations in pyruvate kinase cause deficiency in pyruvate kinase which prevents adequate red blood cell (RBC) glycolysis, leading to a buildup of the upstream glycolytic intermediate 2,3-DPG and deficiency in the pyruvate kinase product ATP.[4][5]

Society and culture

Names

Mitapivat is the international nonproprietary name (INN).[6]

References
  1. "Pyrukynd- mitapivat tablet, film coated PYRUKYND- mitapivat kit". DailyMed. 23 February 2022. Retrieved 3 March 2022.
  2. "Agios Announces FDA Approval of Pyrukynd (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency" (Press release). Agios Pharmaceuticals. 17 February 2022. Retrieved 19 February 2022 – via GlobeNewswire.
  3. Gormley N. "Pyrukynd (mitapivat) tablets NDA approval" (PDF). Center for Drug Evaluation and Research. Letter to Christina Baladi (Agios Pharmaceuticals, Inc.). U.S. Food and Drug Administration.
  4. "Mitapivat (Code C157039)". NCI Thesaurus. 31 January 2022. Retrieved 19 February 2022. This article incorporates text from this source, which is in the public domain.
  5. "PK-R allosteric activator AG-348". NCI Drug Dictionary. National Cancer Institute. Retrieved 19 February 2022. This article incorporates text from this source, which is in the public domain.
  6. World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3): 539. hdl:10665/330961.

Further reading
  • "Mitapivat sulfate". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT03548220 for "A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)" at ClinicalTrials.gov
  • Clinical trial number NCT03559699 for "A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.